Aurora Cannabis Inc. (ACB)
USD 4.24
(-5.15%)
USD 4.24
(-5.15%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 236.8 Million CAD | -42.13% |
| 2022 | 409.18 Million CAD | -3.04% |
| 2021 | 422 Million CAD | -25.58% |
| 2020 | 567.03 Million CAD | -13.73% |
| 2019 | 657.24 Million CAD | -40.94% |
| 2018 | 1.11 Billion CAD | 220.15% |
| 2017 | 347.58 Million CAD | 235.03% |
| 2016 | 103.74 Million CAD | 734.35% |
| 2015 | 12.43 Million CAD | 28.27% |
| 2014 | 9.69 Million CAD | 1715.36% |
| 2013 | 533.98 Thousand CAD | 2093.42% |
| 2012 | 24.34 Thousand CAD | -47.83% |
| 2011 | 46.66 Thousand CAD | 202.2% |
| 2010 | 15.44 Thousand CAD | 0.79% |
| 2009 | 15.32 Thousand CAD | 83.94% |
| 2008 | 8330.00 CAD | 26.69% |
| 2007 | 6575.00 CAD | -55.69% |
| 2006 | 14.84 Thousand CAD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 Q3 | 236.8 Million CAD | -8.56% |
| 2023 FY | 236.8 Million CAD | -42.13% |
| 2023 Q1 | 269.32 Million CAD | -36.18% |
| 2023 Q2 | 258.97 Million CAD | -3.84% |
| 2022 Q4 | 422 Million CAD | 3.13% |
| 2022 Q3 | 409.18 Million CAD | -4.59% |
| 2022 Q2 | 428.85 Million CAD | -25.47% |
| 2022 FY | 409.18 Million CAD | -3.04% |
| 2022 Q1 | 575.43 Million CAD | 36.36% |
| 2021 Q1 | 535.34 Million CAD | -5.59% |
| 2021 Q2 | 530.72 Million CAD | -0.86% |
| 2021 Q3 | 480.16 Million CAD | -9.53% |
| 2021 Q4 | 422 Million CAD | -12.11% |
| 2021 FY | 422 Million CAD | -25.58% |
| 2020 Q4 | 567.03 Million CAD | -13.73% |
| 2020 Q3 | 657.26 Million CAD | 3.83% |
| 2020 Q2 | 633 Million CAD | 4.93% |
| 2020 Q1 | 603.29 Million CAD | -8.21% |
| 2020 FY | 567.03 Million CAD | -13.73% |
| 2019 Q2 | 848.11 Million CAD | -25.63% |
| 2019 Q1 | 1.14 Billion CAD | 2.48% |
| 2019 FY | 657.24 Million CAD | -40.94% |
| 2019 Q3 | 819.39 Million CAD | -3.39% |
| 2019 Q4 | 657.24 Million CAD | -19.79% |
| 2018 Q3 | 1.15 Billion CAD | 100.84% |
| 2018 FY | 1.11 Billion CAD | 220.15% |
| 2018 Q4 | 1.11 Billion CAD | -3.78% |
| 2018 Q2 | 575.83 Million CAD | 4.23% |
| 2018 Q1 | 552.44 Million CAD | 58.94% |
| 2017 Q3 | 284.62 Million CAD | 60.98% |
| 2017 Q4 | 347.58 Million CAD | 22.12% |
| 2017 FY | 347.58 Million CAD | 235.03% |
| 2017 Q1 | 102.91 Million CAD | -0.8% |
| 2017 Q2 | 176.8 Million CAD | 71.8% |
| 2016 Q4 | 103.74 Million CAD | 192.72% |
| 2016 Q1 | 15.67 Million CAD | 26.05% |
| 2016 Q2 | 23.39 Million CAD | 49.26% |
| 2016 Q3 | 35.44 Million CAD | 51.5% |
| 2016 FY | 103.74 Million CAD | 734.35% |
| 2015 FY | 12.43 Million CAD | 28.27% |
| 2015 Q3 | 10.84 Million CAD | -1.28% |
| 2015 Q1 | 10.82 Million CAD | 11.69% |
| 2015 Q2 | 10.98 Million CAD | 1.42% |
| 2015 Q4 | 12.43 Million CAD | 14.7% |
| 2014 Q4 | 9.69 Million CAD | 73.14% |
| 2014 FY | 9.69 Million CAD | 1715.36% |
| 2014 Q1 | 436.97 Thousand CAD | -18.17% |
| 2014 Q3 | 5.59 Million CAD | 17.47% |
| 2014 Q2 | 4.76 Million CAD | 990.69% |
| 2013 Q3 | 7196.00 CAD | 196.25% |
| 2013 FY | 533.98 Thousand CAD | 2093.42% |
| 2013 Q1 | 12.85 Thousand CAD | -47.19% |
| 2013 Q2 | 2429.00 CAD | -81.11% |
| 2013 Q4 | 533.98 Thousand CAD | 7320.62% |
| 2012 Q2 | 8015.00 CAD | -87.66% |
| 2012 Q4 | 24.34 Thousand CAD | 119.21% |
| 2012 FY | 24.34 Thousand CAD | -47.83% |
| 2012 Q1 | 64.94 Thousand CAD | 39.16% |
| 2012 Q3 | 11.1 Thousand CAD | 38.57% |
| 2011 Q3 | 11.23 Thousand CAD | 1277.08% |
| 2011 Q1 | 10.42 Thousand CAD | -32.49% |
| 2011 Q2 | 816.00 CAD | -92.17% |
| 2011 Q4 | 46.66 Thousand CAD | 315.31% |
| 2011 FY | 46.66 Thousand CAD | 202.2% |
| 2010 Q4 | 15.44 Thousand CAD | 9037.87% |
| 2010 FY | 15.44 Thousand CAD | 0.79% |
| 2010 Q3 | 169.00 CAD | -95.2% |
| 2010 Q2 | 3524.00 CAD | -70.84% |
| 2010 Q1 | 12.08 Thousand CAD | -21.13% |
| 2009 Q1 | 11.49 Thousand CAD | 38.04% |
| 2009 Q4 | 15.32 Thousand CAD | 682.93% |
| 2009 FY | 15.32 Thousand CAD | 83.94% |
| 2009 Q3 | 1957.00 CAD | 153.17% |
| 2009 Q2 | 773.00 CAD | -93.28% |
| 2008 FY | 8330.00 CAD | 26.69% |
| 2008 Q1 | 6277.00 CAD | -4.53% |
| 2008 Q3 | 327.00 CAD | 0.0% |
| 2008 Q4 | 8330.00 CAD | 2447.4% |
| 2008 Q2 | - CAD | -100.0% |
| 2007 FY | 6575.00 CAD | -55.69% |
| 2007 Q4 | 6575.00 CAD | 16.21% |
| 2007 Q3 | 5658.00 CAD | 9.46% |
| 2007 Q2 | 5169.00 CAD | -58.91% |
| 2007 Q1 | 12.58 Thousand CAD | 0.0% |
| 2006 FY | 14.84 Thousand CAD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Theratechnologies Inc. | 98.63 Million USD | -140.07% |
| Harrow Health, Inc. | 241.75 Million USD | 2.048% |
| Dynavax Technologies Corporation | 375.02 Million USD | 36.857% |
| Biofrontera Inc. | 23.13 Million USD | -923.393% |
| Cronos Group Inc. | 43.73 Million USD | -441.436% |
| Sonoma Pharmaceuticals, Inc. | 8.75 Million USD | -2604.466% |
| Ironwood Pharmaceuticals, Inc. | 817.36 Million USD | 71.029% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | -388.808% |
| RedHill Biopharma Ltd. | 20.97 Million USD | -1028.809% |
| Cumberland Pharmaceuticals Inc. | 52.51 Million USD | -350.914% |
| Radius Health, Inc. | 804.29 Million USD | 70.558% |
| Universe Pharmaceuticals INC | 13.75 Million USD | -1621.661% |
| DURECT Corporation | 30.4 Million USD | -678.804% |
| ProPhase Labs, Inc. | 42.54 Million USD | -456.607% |
| Safety Shot Inc | 3.89 Million USD | -5984.284% |
| Phibro Animal Health Corporation | 725.54 Million USD | 67.362% |
| China SXT Pharmaceuticals, Inc. | 9.19 Million USD | -2474.894% |
| Alvotech | 1.88 Billion USD | 87.421% |
| Assertio Holdings, Inc. | 148.41 Million USD | -59.554% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | 51.421% |
| Rockwell Medical, Inc. | 30.88 Million USD | -666.799% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -3756.978% |
| Procaps Group S.A. | 462.06 Million USD | 48.751% |
| Intra-Cellular Therapies, Inc. | 136.87 Million USD | -73.012% |
| SCYNEXIS, Inc. | 55.45 Million USD | -327.057% |
| Aytu BioPharma, Inc. | 90.37 Million USD | -162.011% |
| Viatris Inc. | 27.21 Billion USD | 99.13% |
| OptiNose, Inc. | 194.33 Million USD | -21.853% |
| SIGA Technologies, Inc. | 57.97 Million USD | -308.441% |
| Tilray Brands, Inc. | 892.11 Million USD | 73.456% |
| PetIQ, Inc. | 645.22 Million USD | 63.299% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -3756.978% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | 76.77% |
| Guardion Health Sciences, Inc. | 3.77 Million USD | -6177.693% |
| Alimera Sciences, Inc. | 107.35 Million USD | -120.581% |
| Collegium Pharmaceutical, Inc. | 947.87 Million USD | 75.018% |
| Silver Spike Investment Corp. | 3 Million USD | -7767.651% |
| Shuttle Pharmaceuticals Holdings, Inc. | 1.89 Million USD | -12389.84% |
| Organogenesis Holdings Inc. | 181.36 Million USD | -30.569% |
| Journey Medical Corporation | 56.49 Million USD | -319.128% |
| Petros Pharmaceuticals, Inc. | 21.31 Million USD | -1010.929% |
| Alpha Teknova, Inc. | 38.55 Million USD | -514.259% |
| Clever Leaves Holdings Inc. | 7.02 Million USD | -3270.381% |
| Lifecore Biomedical, Inc. | 219.8 Million USD | -7.736% |
| PainReform Ltd. | 2.69 Million USD | -8699.814% |
| Cosmos Health Inc. | 30.25 Million USD | -682.754% |
| Avadel Pharmaceuticals plc | 173.38 Million USD | -36.575% |
| TherapeuticsMD, Inc. | 14.02 Million USD | -1588.796% |
| Embecta Corp. | 2.03 Billion USD | 88.37% |
| Regencell Bioscience Holdings Limited | 219.51 Thousand USD | -107777.018% |
| Talphera, Inc. | 6.29 Million USD | -3664.754% |
| Pacira BioSciences, Inc. | 704.25 Million USD | 66.375% |
| Incannex Healthcare Limited | 5.83 Million USD | -3961.801% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -2689.025% |
| Shineco, Inc. | 47.6 Million USD | -397.468% |
| Procaps Group, S.A. | 462.06 Million USD | 48.751% |
| ANI Pharmaceuticals, Inc. | 471.67 Million USD | 49.795% |
| Aquestive Therapeutics, Inc. | 163.9 Million USD | -44.476% |
| Lantheus Holdings, Inc. | 835.25 Million USD | 71.649% |
| Alvotech | 1.88 Billion USD | 87.421% |
| Hempacco Co., Inc. | 18.82 Million USD | -1158.091% |
| Eagle Pharmaceuticals, Inc. | 172.6 Million USD | -37.198% |
| Bright Green Corporation | 6.43 Million USD | -3578.149% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | 64.164% |
| Kamada Ltd. | 109.96 Million USD | -115.338% |
| Indivior PLC | 1.95 Billion USD | 87.864% |
| Evoke Pharma, Inc. | 9.64 Million USD | -2354.405% |
| Flora Growth Corp. | 17.22 Million USD | -1275.003% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -2689.025% |
| Evolus, Inc. | 209.68 Million USD | -12.932% |
| HUTCHMED (China) Limited | 536.38 Million USD | 55.852% |
| Amphastar Pharmaceuticals, Inc. | 873.49 Million USD | 72.89% |
| Akanda Corp. | 12.66 Million USD | -1769.17% |